Table 4 Comparison of frequently used STOPPFrail-PIM by sex, age, and living condition
STOPPFrail Criteria Section | Sex | Age | Living Condition | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Female (n = 92) | Male (n = 79) | p-value | < 85 years (n = 105) | ≥ 85 years (n = 66) | p-value | Nursing home (n = 69) | Long-term care hospital (n = 102) | p-value | ||||||||
n | % | n | n | n | % | n | % | n | % | n | % | |||||
A2 | Any drug without clear clinical indication | 65 | 70.6 | 65 | 82.3 | 0.76 | 82 | 78.1 | 48 | 72.7 | 0.423 | 50 | 72.5 | 80 | 78.4 | 0.37 |
B1 | Lipid lowering therapies | 32 | 34.8 | 30 | 38.0 | 0.665 | 40 | 38.1 | 22 | 33.3 | 0.528 | 34 | 49.3 | 28 | 27.5 | 0.004 |
D1 | Neuroleptic antipsychotics | 22 | 23.9 | 19 | 24.1 | 0.983 | 25 | 23.8 | 16 | 24.2 | 0.949 | 18 | 26.1 | 23 | 22.5 | 0.595 |
C1 | Antiplatelet for primary prevention | 19 | 20.7 | 18 | 22.8 | 0.736 | 23 | 21.9 | 14 | 21.2 | 0.915 | 22 | 31.9 | 15 | 14.7 | 0.007 |
I1 | Diabetic oral agents for stringent control | 11 | 12.0 | 14 | 17.7 | 0.453 | 19 | 18.1 | 6 | 9.1 | 0.105 | 9 | 13.0 | 16 | 15.7 | 0.631 |
G1 | Calcium supplementation | 14 | 15.2 | 7 | 8.9 | 0.207 | 13 | 12.4 | 8 | 12.1 | 0.960 | 9 | 13.0 | 12 | 11.8 | 0.803 |
D2 | Memantine without BPSD | 10 | 10.9 | 11 | 14.0 | 0.544 | 13 | 12.4 | 8 | 12.1 | 0.960 | 12 | 17.4 | 9 | 8.8 | 0.094 |
J1 | Multivitamins | 7 | 7.6 | 6 | 8.0 | 0.287 | 9 | 8.6 | 4 | 6.1 | 0.105 | 0 | 0 | 13 | 12.7 | - |
E2 | High-dose H2RA (full therapeutic dose with ≥ 8 weeks) | 8 | 8.7 | 5 | 6.3 | 0.560 | 8 | 7.6 | 5 | 7.6 | 0.992 | 2 | 2.9 | 11 | 10.8 | 0.056 |
G4 | Long-term oral NSAIDs (≥ 2 months) | 7 | 7.6 | 6 | 7.6 | 0.991 | 8 | 7.6 | 5 | 7.6 | 0.992 | 10 | 14.5 | 3 | 2.9 | 0.005 |